

Bioorganic & Medicinal Chemistry Letters 10 (2000) 793-795

N-p-Nitrobenzyloxycarbonyl Galactosamine Imidate as a Glycosyl Donor for the Efficient Synthesis of Mucin Core-2 Analogue

Wensheng Liao, Conrad F. Piskorz, Robert D. Locke and Khushi L. Matta*

Molecular & Cellular Biophysics, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263, USA

Received 21 December 1999; accepted 9 February 2000

Abstract—An efficient synthesis of the mucin core-2 analogue 1a was accomplished using *N-p*-nitrobenzyloxycarbonyl(PNZ)-protected trichloroacetimidate 4 as a novel glycosyl donor. © 2000 Elsevier Science Ltd. All rights reserved.

For the last several years we have been involved in the study of glycosyltransferases, specifically α-L-fucosyltransferase, $\alpha(2,3)$ -sialyltransferase, and sulfotransferase responsible for the synthesis of various mucin core 2linked carbohydrate chains. Our recent study indicates that the core-2 branched structure Gal β 1,4GlcNAc β 1, 6(Galβ1,3)GalNAcα is a preferred acceptor for 3-Osulfotransferase^{1a} and $\alpha(2,3)$ -sialyltransferase^{1b} in colon tumor tissues. We have already described the association of the novel $\alpha(1,2)$ -L-fucosylating activity with the Lewis type $\alpha(1,3/4)$ -L-fucosyltransferase, which can convert Gal\beta1,3(Fuc\alpha1,4)GlcNAc (Lea) to Fuc\alpha1,2-Gal β 1,3(Fuc α 1,4)GlcNAc (Le^b).² We are presently investigating an unusual $\alpha(1,2)$ -L-fucosyltransferase capable of converting Gal β 1,4(Fuc α 1,3)GlcNAc (Le^x) to Fuc α 1,2Gal β 1,4(Fuc α 1,3)GlcNAc (Le^y) structure. As we plan to use branched saccharides for this study, molecules 1a and 1b become the target acceptors for this enzyme (Fig. 1). Both acceptors can be used to identify this unique enzyme in the presence of the commonly occurring $\alpha(1,2)$ -L-fucosyltransferase. The present communication describes the chemical synthesis of 1a.

Synthesis of **1a** involves the construction of the Gal-NAc β 1,3GalNAc linkage. However, synthesis of this linkage has not attracted much attention.³ Various galactosamine donors have become available for the synthesis of GalNAc β -linked compounds.⁴ The 1,2*trans*-glycosylation of amino sugars requires glycosyl donors containing participating protective groups in the C2-position. It is important to use a protecting group that can be selectively removed under mild conditions without degradation of the resulting product and other protecting groups. We have investigated various glycosyl donors and finally selected the *N-p*-nitrobenzyloxycarbonyl(PNZ)⁵-protected trichloroacetimidate **4**, which can be readily obtained from galactosamine hydrochloride **2** by five successive high yield conversions. Removal of the PNZ group is also convenient. Simple treatment of *N*-PNZ-protected saccharides with sodium hydrosulphite under neutral conditions provides the free amines. The employment of PNZ avoids the vigorous conditions required for removal of *N*-phthalimido (NPhth) protection,⁶ which is widely used in the synthesis of amino sugars.

Thus, treatment of **2** with one equivalent of NaOMe in MeOH, followed by one equivalent of *p*-nitrobenzyl chloroformate–Et₃N (Scheme 1) gave the *p*-nitrobenzyl carbamate **3**, which was fully *O*-acetylated (Ac₂O–pyr-idine, DMAP). Selective removal of anomeric *O*-acetyl group (hydrazine acetate, DMF) followed by treatment with Cl₃CCN–DBU afforded the key donor **4**, exclusively as α -isomer.

Compound **4** showed high reactivity when used as a glycosyl donor in the presence of either triethylsilyl triflate (Et₃SiOTf) or boron trifluoride diethyl etherate (BF₃·Et₂O) as a promotor (Scheme 2). Disaccharide **6** was obtained in high yield (89%) from the condensation of **4** with **5** in CH₂Cl₂ employing the Et₃SiOTf catalyst. The newly formed β -linkage in **6** was confirmed by ¹³C NMR data which included two signals for C-1_B and C-1_A at δ 101.01 (¹J_{C,H} = 158.5 Hz) and 99.43 (¹J_{C,H} = 168.7 Hz), respectively. Glycosylation by **4** of the diol **11** (Et₃SiOTf, -65°C) afforded the β -(1 \rightarrow 4) linked disaccharide **12** in 78% yield. The glycosylation of **16** (BF₃·Et₂O, -60°C) gave the β -(1 \rightarrow 3) linked disaccharide

^{*}Corresponding author. Tel.: +1-716-845-2397; fax: +1-716-845-3458; e-mail: klmatta@yahoo.com

⁰⁹⁶⁰⁻⁸⁹⁴X/00/\$ - see front matter \odot 2000 Elsevier Science Ltd. All rights reserved. PII: S0960-894X(00)00107-4






Figure 1. This C-2 position is blocked for commonly occurring $\alpha(1,2)$ -L-fucosyltransferase.



Scheme 1. Reagents and conditions: (i) NaOMe–MeOH (1 equiv), rt; (ii) *p*-nitrobenzyl chloroformate–Et₃N (1 equiv), 0° C; (iii) pyridine–Ac₂O, DMAP, 95%; (iv) hydrazine acetate, DMF, 0° C, 2 h, 87%; (v), CCl₃CN (3 equiv)–DBU, CH₂Cl₂, -10° C, 90%.




Scheme 2. Reagents and conditions: (i) 4 (1.5 equiv), TESOTf (0.24 equiv), CH_2Cl_2 , 4 Å molecular sieves, rt, 15 min, 89%; (ii) $Na_2S_2O_4$ (8 equiv), MeCN:EtOH:H₂O (v/v/v 1:1:1), 10 min; (iii) Ac₂O–MeOH; (iv) 75% acetic acid, 45 °C, 2 h, 90%; (v) 80% acetic acid, 40 °C, 2 h, 92%; (vi) 4 (1.2 equiv), TESOTf, CH_2Cl_2 , -65 °C, 1 h, 78%; (vii) pyridine–Ac₂O, DMAP; (viii) 4 (1.2 equiv), BF₃·Et₂O (0.5 equiv), CH_2Cl_2 , -60 °C, 30 min, 82%.

17 in 82% yield. Removal of PNZ from compounds 6, 12 and 17 under mild condition by sodium hydrosulphite⁷ gave 7, 13 and 18 in 80, 77 and 78% yields, respectively. Ensuing *N*-acetylation afforded 8, 14 and 19 in quantitative yields. The above results indicate that a combination of the *N*-PNZ moiety with anomeric trichloroacetimidate activation⁸ in 4 affords an efficient donor for galactosamine β -glycosylation.

With the methodology of effectively constructing Gal-NAc β 1,3GalNAc linkage in hand, we turned our attention to the synthesis of our target compound **1a** (Scheme 3). Initially we tried to use the diol **9**, obtained by hydrolysis of disaccharide **8** in 75% acetic acid at 45 °C, as an acceptor. However, condensation with the Lewis^x donor **21**⁹ under *N*-iodosuccinimide (NIS)–triflic acid (TfOH) condition¹⁰ did not proceed, possibly owing to the poor solubility of 9 in CH₂Cl₂.

In order to increase solubility, the diol **10**, which was directly obtained by treatment of **6** with 80% acetic acid (40 °C, 2 h), was attempted as an acceptor and found to be successful. Thus, glycosylation of **21** with **10** under NIS-TMSOTf condition at -50 °C in CH₂Cl₂ provided the fully protected pentasaccharide **22** in 46% yield. The ¹³C NMR DEPT135 spectra showed a downshift of C-6 in the terminal GalNAc α residue to δ 69.1 ppm, confirming this position as the site of glycosylation. The PNZ group in **22** was reductively cleaved with sodium hydrosulphite. Removal of both the phthalimido and acetate groups from **23** was accomplished by treatment with hydrazine hydrate:ethanol (v/v, 1:4) at 90 °C,



Scheme 3. Reagents and conditions: (i) 21 (1.5 equiv), NIS–TMSOTF, CH_2Cl_2 , 4 Å molecular sieves, $-50 \circ C$, overnight, 46%; (ii) $Na_2S_2O_4$ (8 equiv), MeCN:EtOH:H₂O, 10 min, 65%; (iii) hydrazine hydrate:MeOH (1:4 v/v), 90 °C, 6 h, 90%; (iv) MeOH:Ac₂O (1:1, v/v), 0 °C, quantitative.

followed by *N*-acetylation (Ac₂O–MeOH) to furnish the final product **1a**. The structure of **1a** was confirmed by ¹H, ¹³C NMR and FABMS spectroscopy.¹¹

Acknowledgements

We are grateful to the NIH (CA 35329) for financial support of this research. We thank Dr. E. V. Chandrasekaran for his helpful discussion in preparing this manuscript.

References and Notes

1. (a) Chandrasekaran, E. V.; Jain, R. K.; Vig, R.; Matta, K. L. *Glycobiology* **1997**, *7*, 753; (b) Chandrasekaran, E. V.; Matta, K. L. Manuscript in preparation.

2. Chandrasekaran, E. V.; Jain, R. K.; Rhodes, J. M.; Srnka, C. A.; Larsen, R. D.; Matta, K. L. *Biochemistry* **1995**, *34*, 4748.

3. Barresi, F.; Hindsgaul, O. J. Carbohydr. Chem. 1995, 14 (8), 1043.

4. (a) Castro-Palomino, J. C.; Ritter, G.; Fortunato, S. R.; Reinhardt, S.; Old, L. J.; Schmidt, R. R. Angew. Chem. Int. Ed. Engl. 1997, 36, 1998; (b) Castro-Palomino, J. C.; Schmidt, R. R. Tetrahedron Lett. 1995, 36, 6871; (c) Ellervik, U.; Magnusson, G. Carbohydr. Res. 1996, 280, 251; (d) Jiao, H.; Hindsgaul, O. Angew. Chem., Int. Ed. Engl. 1999, 38, 346; (e) Debenham, J. S.; Madsen, R.; Robert, C.; Fraser-Reid, B. J. Am. Chem. Soc. 1995, 177, 3302.

5. (a) Boullanger, P.; Jouineau, M.; Bouammali, B.; Lafont, D.; Descotes, G. *Carbohydr. Res.* **1990**, *202*, 151; (b) Guibe-Jampel, E.; Wakselman, M. *Synth. Commun.* **1982**, *12*, 219; (c) For corresponding glucosamine derivative as glycosyl donor, see: Qian, X.; Hindsgaul, O. J. Chem. Soc., Chem. Commun. **1997**, 1059.

6. (a) Lemieux, R. U.; Takeda, T.; Chung, B. Y. A.C.S. Symp. Ser. **1976**, 39, 90; (b) Spijker, N. M.; Westerduin, P.; van Boeckel, C. A. A. Tetrahedron **1992**, 48, 6297; (c) Kanie, O.; Crawley, S. C.; Palcic, M. M.; Hindsgaul, O. *Carbohydr. Res.* **1993**, *243*, 139.

7. Typical procedure for removing PNZ group and *N*-acetylation: **6** (0.1 mmol) was dissolved in 4.5 mL CH₃CN:EtOH: H₂O (v/v/v 1:1:1). Sodium hydrosulphite (140 mg) was added and the stirring was continued for 10 min at room temperature. TLC (4:1 CH₂Cl₂:MeOH) indicated that the reaction was complete. The solvent was concentrated and dried over vacuum. Dry MeOH (2.5 mL) and Ac₂O (2 mL) were added successively. After 1 h, the solvent was removed and the residue was purified by column chloromatography (12:1 CH₂Cl₂: MeOH) to afford compound **8** (55 mg, 80%).

8. Schmidt, R. R. Angew. Chem., Int. Ed. Engl. **1986**, 25, 212. 9. Jain, R. K.; Matta, K. L. manuscript in preparation.

10. Konradsson, P.; Udodong, U. E.; Fraser-Reid, B. Tetrahedron Lett. 1990, 31, 4313.

11. Selected data for 4: ¹H NMR (CDCl₃, 400 MHz) δ 8.78 (s, 1H, C = NH, 8.20 (d, 2H, J = 9.2 Hz, arom H), 7.47 (d, 2H, J = 8.4 Hz, arom H), 6.45 (d, 1H, J = 4.0 Hz, H-1), 5.50 (d, 1H, J=2.4 Hz, H-4), 5.26 (dd, 1H, J=3.0, J=11.8 Hz, H-3), 5.19 (s, 2H, OCOCH₂PhNO₂), 4.94 (d, 1H, J=10.0 Hz, NHPNZ), 4.57 (m, 1H, H-2), 4.20-4.04 (m, 3H, H-5, H-6), 2.18, 2.01, 1.99 (3 s, 9H, 3 OAc); for 6: ¹H NMR (CDCl₃, 400 MHz) δ 8.14 (d, 2H, J=7.2 Hz, arom H), 7.45 (d, 2H, J=8.8 Hz, arom H), 7.44 (d, 2H, J=8.8 Hz, arom H), 6.85 (d, 2H, J=8.4 Hz, arom H), 5.74 (d, 1H, J=8.8 Hz, H-1'), 5.49 (s, 1H, MeO PhCH), 5.35 (d, 1H, J = 2.8 Hz, H-4'), 4.85 (d, 1H, J = 3.2 Hz, H-1), 4.28 (d, 1H, J=2.8 Hz, H-4), 3.78, 3.41 (2 s, 6H, 2 OCH₃), 2.17, 2.05, 1.94, 1.92 (4 s, 12H, 4 COCH₃); ¹³C NMR (CDCl₃, 100.6 MHz) δ 170.63, 170.46, 170.31, 170.24 (4 CO), 101.01 $(J_{C1'H1'} = 158.5 \text{ Hz}, \text{C-1'}), 99.43 (J_{C1H1} = 168.7 \text{ Hz}, \text{C-1}),$ 69.34 (C-6), 61.74 (C-6'), 55.48, 55.33 (2 OCH₃), 23.31, 20.75, 20.70, 20.60 (4 COCH₃); for 1: FABMS *m*/*z* 972.7 [M + Na]⁺; ¹H NMR (D₂O, 400 MHz) δ 5.13 (d, 1H, J=3.6 Hz, H-1^{*iii*} 4.81 (d, 1H, J=3.7 Hz, H-1), 4.58 (d, 1H, J=8.0 Hz, H-1"), 4.53 (d, 1H, J=8.0 Hz, H-1^{'''}), 4.48 (d, 1H, J=7.6 Hz, H-1^{''}), 3.36 (s, 3H, OCH₃), 2.06, 2.04, and 2.02 (each s, 9H, $3 \times \text{NHAc}$), 1.20 (d, 3H, J = 6.4 Hz, CMe); ¹³C NMR (D₂O, 100.6 MHz) δ 173.53, 173.10, 172.63 (3 CO), 101.68 (C-1"'), 100.82 (C-1'), 100.34 (C-1"), 97.60 (C-1""), 97.12 (C-1), 54.69 (OMe), 21.29, 21.26, 21.04 (3×NHAc), 14.27 (C-6"").